Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes

被引：6
|
作者：
Kumar, Hari K. V. S. [1 ]
机构：
[1] Command Hosp, Chandimandir, India
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 373卷 / 25期
关键词：
D O I：
10.1056/NEJMc1510995
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2478 / 2478
页数：1
相关论文
共 50 条
  • [1] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Buse, John B.
    Engel, Samuel S.
    Garg, Jyotsna
    Josse, Robert
    Kaufman, Keith D.
    Koglin, Joerg
    Korn, Scott
    Lachin, John M.
    McGuire, Darren K.
    Pencina, Michael J.
    Standl, Eberhard
    Stein, Peter P.
    Suryawanshi, Shailaja
    Van de Werf, Frans
    Peterson, Eric D.
    Holman, Rury R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03): : 232 - 242
  • [2] Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
    Cornel, Jan H.
    Bakris, George L.
    Stevens, Susanna R.
    Alvarsson, Michael
    Bax, Willem A.
    Chuang, Lee-Ming
    Engel, Samuel S.
    Lopes, Renato D.
    McGuire, Darren K.
    Riefflin, Axel
    Rodbard, Helena Wachslicht
    Sinay, Isaac
    Tankova, Tsvetalina
    Wainstein, Julio
    Peterson, Eric D.
    Holman, Rury R.
    [J]. DIABETES CARE, 2016, 39 (12) : 2304 - 2310
  • [3] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (vol 373, pg 232, 2015)
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (06): : 586 - 586
  • [4] Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
    Engel, S. S.
    Suryawanshi, S.
    Josse, R. G.
    Peterson, E. D.
    Holman, R. R.
    [J]. DIABETOLOGIA, 2016, 59 : S361 - S361
  • [5] Assessing the Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
    Engel, Samuel S.
    Suryawanshi, Shailaja
    Josse, Robert G.
    Peterson, Eric
    Holman, Rury R.
    [J]. DIABETES, 2016, 65 : A310 - A310
  • [6] Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
    Zeng, De-kang
    Xiao, Qian
    Li, Fa-qi
    Tang, Yu-zhi
    Jia, Chao-li
    Tang, Xue-wen
    [J]. BIOSCIENCE REPORTS, 2019, 39
  • [7] Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
    Chi, Cecilia
    Snaith, Jennifer
    Gunton, Jenny E.
    [J]. HEART LUNG AND CIRCULATION, 2017, 26 (11): : 1133 - 1141
  • [8] Cardiovascular outcomes in type 1 and type 2 diabetes
    Rosengren, Annika
    Dikaiou, Pigi
    [J]. DIABETOLOGIA, 2023, 66 (03) : 425 - 437
  • [9] Cardiovascular outcomes in type 1 and type 2 diabetes
    Annika Rosengren
    Pigi Dikaiou
    [J]. Diabetologia, 2023, 66 : 425 - 437
  • [10] Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Samuel S Engel
    Gregory T Golm
    Deborah Shapiro
    Michael J Davies
    Keith D Kaufman
    Barry J Goldstein
    [J]. Cardiovascular Diabetology, 12
12345